Latest Breonics News

BREONICS, INC. Appoints Seth Green as CEO and member of Board of Directors

Albany, New York (October 5, 2010) BREONICS, Inc., a pioneer in Organ Regeneration Research, today announced the appointment of Seth Green as Chief Executive Officer and a member of the company's Board of Directors, effective October 6th. Green most recently served as a strategy consultant with Deloitte Consulting and brings a wealth of experience to BREONICS at a time when the company is moving into commercialization of its patent portfolio.

Ernest Green, Chairman of BREONICS, said, "We are delighted to have an executive with Seth’s leadership and sound business perspective to lead BREONICS as the company moves into a new phase of its mission to solve the world-wide kidney shortage. Seth is ideally qualified to lead commercialization of the company’s technologies." Ernest Green will remain with the company in the role of Chairman. Splitting the duties will allow him to focus on activities at the transplantation centers involved in the company’s most recent grant from the National Institute of Health.

Seth Green is a 1996 graduate of the United States Military Academy at West Point. He is also a 2005 graduate of the Tuck School of Business at Dartmouth where he received his MBA. While in the Army, he led units in both Kosovo and Iraq. With Deloitte, he worked across a variety of industries in the firm’s Strategy and Operations Practice.

"This is an exciting time to join the BREONICS team," said Green. "The biotech’s research is on the frontier of applied nanotechnology in the field of regenerative medicine-- its technology has the potential to alter the organ donor paradigm, exponentially increasing the number of kidneys available for transplantation."

BREONICS, INC. prevails over Vitrolife in European Patent Opposition

Albany, New York (September 29, 2010) On September 29th, the European Patent Office (EPO) upheld US-based BREONICS' European Patent No. 1021084, which relates inter alia to a proprietary organ transplant system known as the Exsanguinous Metabolic Support (EMS). In doing so, the EPO dismissed (on all substantive points) a validity challenge by Swedish-based VitroLife. BREONICS' European patent provides protection for a novel technology that that can be used to intervene after cardiac arrest and repair ischemically damaged kidneys for transplantation. The unique ability of EMS changes today’s limitation of recovering cadaveric kidneys from within minutes of death to a window of several hours postmortem. This significantly broadens the criteria for organ donation to include those patients who are declared dead from cardiac arrest at an accident scene in the ER or in the hospital.

“This ruling is an important legal endorsement of the pioneering work that BREONICS has done over the last decade on the use of warm perfusion to increase the supply of organs available for transplantation,” said Ernie Green, Chairman of BREONICS. The ruling is an important victory for the small biotech as it seeks regulatory approval for the EMS system in its efforts to commercialize the organ transplantation technology.


page 1    page 2